IP Library Granted Patent US 9,220,697
Granted Patent B2
US 9,220,697 · App. 12/914,844 · Granted Dec 29, 2015

Compositions and methods for diagnosis and treatment of epilepsy

Inventors: Antonio V. Delgado-Escueta (Malibu, CA); Kazuhiro Yamakawa (Saitama, JP); Toshimitsu Suzuki (Saitama, JP); Marco Tulio Medina-Hernandez (Tegucigalpa, HN); Maria Elisa Alonso Vilatela (Delegacion, MX)
A61K31/19C07K16/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,220,697
App. No.
12/914,844
Granted
Dec 29, 2015
Kind
B2
Abstract

Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1 a , EFHC1 a agonists, or EFHC1 a analogs are provided.

Claims (9)

1. A method of detecting a polymorphism in an EFHC1 gene in a human subject, comprising:

(a) providing a biological sample from a human subject, wherein the sample comprises all, or a portion of, an EFHC1 gene;

(b) contacting one or more labeled oligonucleotide probes under stringent hybridization conditions to the EFHC1 gene or the portion thereof, wherein each oligonucleotide probe is capable of hybridizing to a portion of the EFHC1 gene comprising the 330C>A or 763G>A polymorphism under stringent hybridization conditions but incapable of hybridizing to a portion of the EFHC gene that does not comprise the 330C>A and 763G>A polymorphisms under stringent hybridization conditions, wherein the EFHC1 gene comprises at least 85% sequence identity to SEQ ID NO: 3; and

(c) detecting hybridization of the one or more labelled oligonucleotides with the EFHC1 gene or the portion thereof under stringent hybridization conditions;

(d) detecting a polymorphism in an EFHC1 gene in the human subject.

2. The method of claim 1 , wherein the probe is between 10 to 40 nucleotides in length.

3. The method of claim 1 , wherein the-subject is at risk of juvenile myoclonic epilepsy (JME).

4. The method of claim 1 , further comprising amplifying by PCR the EFHC1 gene or the portion thereof.

5. The method of claim 1 , wherein the sample comprises neuronal cells.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2015
From: YAMAKAWA, KAZUHIRO; SUZUKI, TOSHIMITSU
To: RIKEN
Reel/Frame 035622/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2015
From: DELGADO-ESCUETA, ANTONIO V
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 035622/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2015
From: VILATELA, MARIA ELISA ALONSO
To: INSTITUTO NACIONAL DE NEUROLOGIA Y NEUROCIRUGIA MANUEL VELASCO SUAREZ
Reel/Frame 035622/0258 →
CONFIRMATORY LICENSE Recorded Feb 12, 2013
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029793/0849 →
Continuity (3)
Continuation 11572201
Provisional Application 60588769 · Jul 16, 2004
Related Publication 20110287418A1 · Nov 24, 2011